Natural killer cells in cutaneous malignant melanoma
- 1 May 1990
- journal article
- research article
- Published by Wiley in The Journal of Pathology
- Vol. 161 (1) , 35-40
- https://doi.org/10.1002/path.1711610107
Abstract
Using immunocytochemical techniques on fresh surgical samples, a series of 16 cases of cutaneous malignant melanoma (CMM) were examined to characterize further the host inflammatory response. Antibodies to the following cluster of differentiation (CD) antigens were used: CD‐3, CD‐4, CD‐8 (T‐cell markers), CD‐11b, CD‐14 (macrophage marker), CD‐16 [an antigen expressed by natural killer (NK) cells and granulocytes], and CD‐25. Also examined were a small number of other melanocytic lesions [two cases of lentigo maligna (Hutchinson's melanotic freckle) and five of intradermal naevi]. The results of the study document a population of cells with the morphological and immunophenotypic characteristics of NK cells in association with 10 of the 16 cases of CMM. These cells were consistently absent from the other melanocytic lesions studied. The presence of NK cells in association with some cases of CMM bears no clear relationship to the Breslow thickness, Clark level, tumour ulceration, or the presence of activated T cells as determined by expression of the CD‐25 antigen. Whilst an explanation for the significant numbers of NK cells in some CMM lesions is unclear, their presence in intimate association with tumour cells does prompt speculation regarding a possible role in determining the biological behaviour of the tumour. Additionally, the study has confirmed and extended previous findings with respect to the broad characterization of mononuclear cells present in the host infiltrate associated with CMM.Keywords
This publication has 29 references indexed in Scilit:
- Interleukin‐2 receptor expression in benign and malignant melanocytic skin lesionsThe Journal of Pathology, 1989
- Histological evidence of natural killer cell aggregation against malignant melanoma induced by adoptive immunotherapy with lymphokine-activated killer cellsThe Journal of Pathology, 1989
- Lymphokine-activated killer cell activity: Characteristics of effector cells and their progenitors in blood and spleenImmunology Today, 1987
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced CancerNew England Journal of Medicine, 1987
- Natural Killer CellsAnnual Review of Medicine, 1986
- Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic CancerNew England Journal of Medicine, 1985
- Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes).Journal of Histochemistry & Cytochemistry, 1984
- T cell subsets and Langerhans cells in skin tumoursEuropean Journal of Cancer and Clinical Oncology, 1983
- Inhibition of endogenous tissue alkaline phosphatase with the use of alkaline phosphatase conjugates in immunohistochemistry.Journal of Histochemistry & Cytochemistry, 1981